News Releases

Year

03 Sep '24

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 3, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye , M.D., Quince’s Chief Executive

PDF Version

15 Aug '24

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Findings from largest completed study in A-T demonstrated favorable safety profile Study showed positive effect of EryDex treatment in a subset of patients with A-T ages six to nine – the age range that typically experiences rapid clinical decline Quince recently initiated pivotal Phase 3 NEAT

PDF Version

13 Aug '24

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Strong cash position expected to provide sufficient operating runway into 2026; Phase 3 topline results expected in the fourth quarter of 2025 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 13, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to

PDF Version

25 Jun '24

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 25, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today announced that the

PDF Version

03 Jun '24

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Fast Track designation underscores the high unmet medical need, with currently no approved therapeutic treatments for the rare pediatric disease Ataxia-Telangiectasia SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 3, 2024-- Quince Therapeutics, Inc.

PDF Version

13 May '24

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 13, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today provided an update on

PDF Version

06 May '24

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 6, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today announced that Dirk

PDF Version

01 Apr '24

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 1, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today provided an update on

PDF Version

22 Feb '24

Quince Therapeutics Launches Scientific Advisory Board

World-renowned scientists and clinicians to provide expert insight and advice to support advancement of the company’s lead Phase 3 asset, new indications, and pipeline expansion SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 22, 2024-- Quince Therapeutics, Inc.

PDF Version

15 Feb '24

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 15, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced the appointment

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12